Using this inhibitor, 11, we determined that ERK5 inhibits the tumor suppressor activity of cellular promyelocytic leukemia protein (PML) and demonstrated efficacy and tolerability of the inhibitor against two tumor xenografts providing preliminary support for further exploration of ERK5 inhibitors as anti-cancer agents [20]. Here, PML is linked to cancer.